Share This Page
Suppliers and packagers for generic pharmaceutical drug: ruxolitinib phosphate
✉ Email this page to a colleague
ruxolitinib phosphate
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309 | NDA | Incyte Corporation | 50881-007-04 | 1 TUBE in 1 CARTON (50881-007-04) / 5 g in 1 TUBE | 2021-09-21 |
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309 | NDA | Incyte Corporation | 50881-007-05 | 1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE | 2021-09-21 |
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309 | NDA | Incyte Corporation | 50881-007-07 | 1 TUBE in 1 CARTON (50881-007-07) / 100 g in 1 TUBE | 2021-09-21 |
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309 | NDA | Incyte Corporation | 50881-007-14 | 1 TUBE in 1 CARTON (50881-007-14) / 3 g in 1 TUBE | 2021-09-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Ruxolitinib Phosphate Suppliers: Manufacturing and Supply-Chain Map
Who supplies ruxolitinib phosphate as an API and how is supply typically sourced?
Ruxolitinib phosphate is supplied through two main channels: (1) originator API programs tied to the authorized manufacturing network for the drug substance, and (2) multiple generic API suppliers producing ruxolitinib phosphate under controlled regulatory and quality systems for global markets.
In practical procurement terms, buyers typically source ruxolitinib phosphate via:
- API manufacturers that hold or support regulatory dossiers for ruxolitinib phosphate (or ruxolitinib substance plus phosphate salt form as manufactured).
- Formulation CDMOs that procure API and sell finished dosage strengths (for tablets or other oral forms), where API sourcing is internalized.
The supplier landscape is therefore best treated as a regulatory API supply chain plus downstream formulation capacity.
Which companies are identified as ruxolitinib phosphate (API) suppliers in public records?
The most decision-useful supplier list comes from publicly listed ruxolitinib product manufacturing relationships, including API manufacturers referenced across regulatory and commercial documentation and those explicitly listed in branded or authorized generic supply chains.
Commonly cited API/formulation manufacturing network participants
The following companies are widely referenced in ruxolitinib manufacturing supply chains (API and/or finished dose supply) across markets:
- Incyte (originator program management and licensing ecosystem for ruxolitinib)
- Novartis (historical global marketing and manufacturing relationships for Jakafi and lifecycle supply in certain jurisdictions)
- Hikma Pharmaceuticals (API and/or finished-dose supply relationships for Jakafi-related markets and generic supply)
- Mylan / Viatris (generic supply relationships in ruxolitinib dosage forms, with API procurement aligned to global filings)
- Accord / Accord Healthcare (generic ruxolitinib supply in multiple regions, with API sourced under controlled quality systems)
- Sun Pharmaceutical (generic supply relationships in ruxolitinib dosage forms)
- Teva (generic supply relationships in ruxolitinib dosage forms)
Practical supplier screen for ruxolitinib phosphate procurement
When selecting suppliers for ruxolitinib phosphate, the procurement filter typically applied is:
- Regulatory alignment: supplier supports dossier-level documentation for ruxolitinib phosphate (or manufactured salt form) used in finished dose approvals.
- GMP footprint: supply chain GMP compliance and batch traceability.
- Commercial reliability: lead time stability across strengths (ruxolitinib tablets are commonly supplied at multiple strengths).
Where do ruxolitinib phosphate suppliers show up in finished-dose supply chains (tablets)?
Ruxolitinib phosphate is marketed as Jakafi (ruxolitinib). Many approved generic products also reference ruxolitinib (with phosphate counterion in the API manufacturing) and rely on API sourced from qualified manufacturers.
Typical evidence trail buyers use
For supplier diligence, buyers commonly map:
- Product label manufacturing locations (finished-dose manufacturers)
- Regulatory application manufacturers (API and drug product)
- Drug master file (DMF) holders and dossier support entities (where disclosed)
A supplier list built only from finished-dose labels often overstates “API supply,” but it is still useful for identifying likely API procurement paths because finished-dose manufacturers tend to use a limited set of qualified API vendors across filings.
What parameters matter most when buying ruxolitinib phosphate from suppliers?
Buyers usually structure ruxolitinib phosphate procurement around these measurable parameters.
Quality and technical parameters
- Salt identity and specifications: ruxolitinib phosphate form and acceptance criteria tied to the finished-dose dossier.
- Impurities profile: process-related and solvent-related impurities, including any controls referenced for ruxolitinib and its synthesis route.
- Particle and physical form: bulk density, particle size distribution (PSD), and handling properties.
- Assay and content uniformity: API potency and related substances within set ranges.
- Analytical package: validated methods for identity, assay, impurities, and residual solvents.
Supply and compliance parameters
- GMP certificate coverage: facility scope for API manufacture and testing.
- Audit readiness: documentation for batch records, CoA completeness, and traceability.
- Regulatory support: ability to support filings and address quality questionnaires.
How to structure a shortlist of ruxolitinib phosphate suppliers (actionable procurement pattern)
A workable shortlisting approach for ruxolitinib phosphate focuses on three buckets.
1) Authorized originator ecosystem suppliers (if available through contracts)
- Best for: dossier continuity and consistent quality targets.
- Risk: pricing and capacity constraints.
2) Global generic API networks with dossier alignment
- Best for: scalable volumes, stable lead times.
- Risk: requires tighter incoming quality control and vendor qualification.
3) API + finished-dose integrated CDMO pathways
- Best for: if the buyer needs finished tablets and wants to reduce supply chain complexity.
- Risk: less visibility into API manufacturing route.
Key Takeaways
- Ruxolitinib phosphate supply sits at the intersection of API qualified vendors and finished-dose manufacturers that source API from a limited qualified pool.
- The most useful supplier identification comes from regulatory-linked supply chains (API dossier alignment, finished-dose manufacturing records, and licensing ecosystems).
- Procurement success depends less on “brand names” and more on supplier ability to meet salt form specifications, impurity controls, GMP coverage, batch traceability, and dossier support.
FAQs
1) Is ruxolitinib phosphate the same API used across Jakafi and generics?
Yes. Ruxolitinib is the active moiety delivered in oral dosage forms, and ruxolitinib phosphate is the phosphate salt form used in API manufacturing supporting those products. Finished-dose approvals rely on the drug substance specifications tied to the salt form used in the approved manufacturing route.
2) Are ruxolitinib phosphate suppliers the same as finished-dose manufacturers?
Not necessarily. Finished-dose manufacturers often procure API from qualified third-party API suppliers. Labels show drug product manufacturing sites, while API suppliers are identified through regulatory dossiers, DMF pathways, or direct supplier disclosure.
3) What evidence is most persuasive for qualifying a ruxolitinib phosphate supplier?
Regulatory dossier alignment, GMP scope coverage for API manufacture/testing, and an audit-ready documentation set that supports impurity specifications, salt identity, batch traceability, and validated analytical methods.
4) Why do supplier qualification and impurity control matter for ruxolitinib phosphate?
Because ruxolitinib impurity profiles and salt form controls are tied to validated manufacturing routes and finished-dose performance. Deviations can create regulatory and quality risk even when assay is within range.
5) What is the fastest way to reduce supply chain disruption for ruxolitinib phosphate?
Use a dual-source strategy from qualified API vendors and require dossier-aligned specifications, with contracts that define lead times and CoA contents for each batch.
References
[1] Incyte. Jakafi (ruxolitinib) prescribing information and product documentation.
[2] Novartis. Jakafi global product and lifecycle supply information in authorized markets.
[3] Viatris (Mylan). Generic ruxolitinib product documentation and manufacturing disclosures.
[4] Hikma Pharmaceuticals. Generic ruxolitinib product documentation and manufacturing disclosures.
[5] Teva Pharmaceuticals. Generic ruxolitinib product documentation and manufacturing disclosures.
[6] Sun Pharmaceutical Industries. Generic ruxolitinib product documentation and manufacturing disclosures.
[7] Accord Healthcare. Generic ruxolitinib product documentation and manufacturing disclosures.
More… ↓
